{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T16:04:27Z","timestamp":1785600267519,"version":"3.56.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31871414"],"award-info":[{"award-number":["31871414"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81673489"],"award-info":[{"award-number":["81673489"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["16430724100"],"award-info":[{"award-number":["16430724100"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012692","name":"K. C. Wong Education Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012692","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.bbrc.2019.02.065","type":"journal-article","created":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T08:18:44Z","timestamp":1550650724000},"page":"387-393","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Alogliptin alleviates liver fibrosis via suppression of activated hepatic stellate cell"],"prefix":"10.1016","volume":"511","author":[{"given":"Hanyan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanzhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shichao","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Field","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2019.02.065_bib1","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.cld.2008.07.011","article-title":"Current and future anti-fibrotic therapies for chronic liver disease","volume":"12","author":"Rockey","year":"2008","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.bbrc.2019.02.065_bib2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev-pathol-011110-130246","article-title":"Pathogenesis of liver fibrosis","volume":"6","author":"Hernandez-Gea","year":"2011","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.bbrc.2019.02.065_bib3","doi-asserted-by":"crossref","first-page":"G709","DOI":"10.1152\/ajpgi.00451.2010","article-title":"Therapeutic targets in liver fibrosis","volume":"300","author":"Fallowfield","year":"2011","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.bbrc.2019.02.065_bib4","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.jhep.2015.03.039","article-title":"Mechanisms of liver fibrosis resolution","volume":"63","author":"Tacke","year":"2015","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.bbrc.2019.02.065_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20071570","article-title":"Liver fibrosis","volume":"411","author":"Wallace","year":"2008","journal-title":"Biochem. J."},{"key":"10.1016\/j.bbrc.2019.02.065_bib6","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1172\/JCI66369","article-title":"Hepatic stellate cells in liver development, regeneration, and cancer","volume":"123","author":"Yin","year":"2013","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.bbrc.2019.02.065_bib7","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1172\/JCI93562","article-title":"The balancing act of the liver: tissue regeneration versus fibrosis","volume":"128","author":"Cordero-Espinoza","year":"2018","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.bbrc.2019.02.065_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41232-016-0005-6","article-title":"Roles of hepatic stellate cells in liver inflammation: a new perspective","volume":"36","author":"Fujita","year":"2016","journal-title":"Inflamm. Regen."},{"key":"10.1016\/j.bbrc.2019.02.065_bib9","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.bbrc.2019.02.065_bib10","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1016\/S0140-6736(14)62225-X","article-title":"Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial","volume":"385","author":"Faiez","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.bbrc.2019.02.065_bib11","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.hrthm.2015.03.010","article-title":"Alogliptin, a dipeptidyl peptidase-4 inhibitor, regulates the atrial arrhythmogenic substrate in rabbits","volume":"12","author":"Yamamoto","year":"2015","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.bbrc.2019.02.065_bib12","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12933-017-0558-y","article-title":"The regulatory role of DPP4 in atherosclerotic disease","volume":"16","author":"Duan","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.bbrc.2019.02.065_bib13","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00535-013-0783-4","article-title":"Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats","volume":"49","author":"Kaji","year":"2014","journal-title":"J.\u00a0Gastroenterol."},{"key":"10.1016\/j.bbrc.2019.02.065_bib14","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.biopha.2017.02.010","article-title":"Combination of Sitagliptin and Silymarin ameliorates liver fibrosis induced by carbon tetrachloride in rats","volume":"89","author":"Sokar","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbrc.2019.02.065_bib15","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1111\/hepr.12860","article-title":"Combined treatment with dipeptidyl peptidase-4 inhibitor (sitagliptin) and angiotensin-II type 1 receptor blocker (losartan) suppresses progression in a non-diabetic rat model of steatohepatitis","volume":"47","author":"Okura","year":"2017","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.bbrc.2019.02.065_bib16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.addr.2017.05.007","article-title":"Hepatic stellate cells as key target in liver fibrosis","volume":"121","author":"Higashi","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bbrc.2019.02.065_bib17","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1111\/febs.13665","article-title":"TGF-beta signalling and liver disease","volume":"283","author":"Fabregat","year":"2016","journal-title":"FEBS J."},{"issue":"2012","key":"10.1016\/j.bbrc.2019.02.065_bib18","first-page":"158547","article-title":"Cell signals influencing hepatic fibrosis","volume":"2012","author":"Cong","year":"2012","journal-title":"Bangladesh Liver J."},{"key":"10.1016\/j.bbrc.2019.02.065_bib19","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1369\/0022155415627681","article-title":"TGF-beta\/SMAD pathway and its regulation in hepatic fibrosis","volume":"64","author":"Xu","year":"2016","journal-title":"J.\u00a0Histochem. Cytochem."},{"key":"10.1016\/j.bbrc.2019.02.065_bib20","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: a multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.bbrc.2019.02.065_bib21","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41575-018-0009-6","article-title":"Triggering and resolution of inflammation in NASH","volume":"5","author":"Schuster","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbrc.2019.02.065_bib22","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3389\/fimmu.2015.00386","article-title":"DPP4 in diabetes","volume":"6","author":"Rohrborn","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrc.2019.02.065_bib23","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1097\/PRS.0000000000002634","article-title":"Dipeptidyl peptidase-4, wound healing, scarring, and fibrosis","volume":"138","author":"Hu","year":"2016","journal-title":"Plast. Reconstr. Surg."},{"key":"10.1016\/j.bbrc.2019.02.065_bib24","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1042\/bj2620327","article-title":"Evidence for a role of dipeptidyl peptidase IV in fibronectin-mediated interactions of hepatocytes with extracellular matrix","volume":"262","author":"Piazza","year":"1989","journal-title":"Biochem. J."},{"key":"10.1016\/j.bbrc.2019.02.065_bib25","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.3748\/wjg.v19.i15.2298","article-title":"Dipeptidyl peptidase-4: a key player in chronic liver disease","volume":"19","author":"Itou","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.bbrc.2019.02.065_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13069-016-0038-0","article-title":"Dipeptidyl peptidase-4 and kidney fibrosis in diabetes","volume":"9","author":"Shi","year":"2016","journal-title":"Fibrogenesis Tissue Repair"},{"key":"10.1016\/j.bbrc.2019.02.065_bib27","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3892\/br.2016.569","article-title":"Efficacy of alogliptin in preventing non-alcoholic fatty liver disease progression in patients with type 2 diabetes","volume":"4","author":"Mashitani","year":"2016","journal-title":"Biomed Rep"},{"key":"10.1016\/j.bbrc.2019.02.065_bib28","article-title":"Non-alcoholic fatty liver disease - a global public health perspective","author":"Younossi","year":"2018","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.bbrc.2019.02.065_bib29","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/03602532.2017.1293683","article-title":"Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters","volume":"49","author":"Cobbina","year":"2017","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.bbrc.2019.02.065_bib30","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/iub.1709","article-title":"Significance of circulatory DPP4 activity in metabolic diseases","volume":"70","author":"Nargis","year":"2018","journal-title":"IUBMB Life"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X1930258X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X1930258X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T21:13:01Z","timestamp":1576703581000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X1930258X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0006291X1930258X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2019.02.065","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alogliptin alleviates liver fibrosis via suppression of activated hepatic stellate cell","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2019.02.065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}